Compass Therapeutics (CMPX) Total Debt (2019 - 2021)

Compass Therapeutics' Total Debt history runs 3 years deep, the most recent figure standing at $3.7 million for Q3 2021.

• In Q3 2021, Total Debt fell 66.54% year-over-year to $3.7 million; the TTM figure through Sep 2021 stood at $3.7 million (down 66.54% YoY), while the FY2020 annual figure was $9.3 million, down 4.63% from the prior year.
• Total Debt came in at $3.7 million for Q3 2021 at Compass Therapeutics, down from $7.5 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $13.0 million in Q2 2020 to a low of $3.7 million in Q3 2021.
• A 3-year average of $9.1 million and a median of $9.6 million in 2019 frame the typical range for Total Debt.
• Across the five-year window, Total Debt retreated 4.63% in 2020 and tumbled 66.54% in 2021, its largest moves.
• Compass Therapeutics' Total Debt stood at $9.8 million in 2019, then decreased by 4.63% to $9.3 million in 2020, then tumbled by 59.89% to $3.7 million in 2021.
• According to Business Quant data, Total Debt over the past three periods registered $3.7 million, $7.5 million, and $9.3 million for Q3 2021, Q1 2021, and Q4 2020 respectively.

Peer Comparison